AU1626199A - A vi-repa conjugate vaccine for immunization against salmonella typhi - Google Patents
A vi-repa conjugate vaccine for immunization against salmonella typhiInfo
- Publication number
- AU1626199A AU1626199A AU16261/99A AU1626199A AU1626199A AU 1626199 A AU1626199 A AU 1626199A AU 16261/99 A AU16261/99 A AU 16261/99A AU 1626199 A AU1626199 A AU 1626199A AU 1626199 A AU1626199 A AU 1626199A
- Authority
- AU
- Australia
- Prior art keywords
- salmonella typhi
- conjugate vaccine
- immunization against
- against salmonella
- repa conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010060123 Conjugate Vaccines Proteins 0.000 title 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 title 1
- 229940031670 conjugate vaccine Drugs 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/025746 WO2000033882A1 (en) | 1998-12-04 | 1998-12-04 | A vi-repa conjugate vaccine for immunization against salmonella typhi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1626199A true AU1626199A (en) | 2000-06-26 |
Family
ID=22268424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU16261/99A Abandoned AU1626199A (en) | 1998-12-04 | 1998-12-04 | A vi-repa conjugate vaccine for immunization against salmonella typhi |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1626199A (en) |
| WO (1) | WO2000033882A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| KR101408113B1 (en) † | 2005-06-27 | 2014-06-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Process for manufacturing vaccines |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| ATE553774T1 (en) | 2007-10-19 | 2012-05-15 | Novartis Ag | MENINGOCOCCAL VACCINE FORMULATIONS |
| BRPI0907843A2 (en) | 2008-02-21 | 2015-08-04 | Novartis Ag | Menigococcal fhbp polypeptides |
| PL2349520T3 (en) | 2008-10-27 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Purification method for carbohydrate from group a streptococcus |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| RU2557315C2 (en) | 2009-03-24 | 2015-07-20 | Новартис Аг | Factor h-binding adjuvant meningococcal protein |
| NZ595291A (en) | 2009-03-24 | 2013-08-30 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| MX2011010735A (en) | 2009-04-14 | 2012-01-25 | Novartis Ag | Compositions for immunising against staphylococcus aerus. |
| CN102596240B (en) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | Hybrid polypeptides including meningococcal fHBP sequences |
| KR20120081587A (en) | 2009-09-10 | 2012-07-19 | 노파르티스 아게 | Combination vaccines against respiratory tract diseases |
| WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| BR112012010531A2 (en) | 2009-10-27 | 2019-09-24 | Novartis Ag | "fhbp meningococcal modification polypeptides" |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| ES2612511T3 (en) | 2011-01-27 | 2017-05-17 | Glaxosmithkline Biologicals Sa | Adjuvant nanoemulsions with crystallization inhibitors |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| EP2688590B1 (en) | 2011-03-24 | 2020-02-12 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with phospholipids |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| TR201909110T4 (en) | 2011-09-14 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Methods for making saccharide-protein glycoconjugates. |
| CN104080479B (en) | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | Carrier molecules including spr0096 and spr2021 antigen |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| WO2013098589A1 (en) | 2011-12-29 | 2013-07-04 | Novartis Ag | Adjuvanted combinations of meningococcal factor h binding proteins |
| WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
| US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
| WO2014053612A1 (en) | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic composition |
| SG11201504258RA (en) | 2012-11-30 | 2015-07-30 | Glaxosmithkline Biolog Sa | Pseudomonas antigens and antigen combinations |
| WO2014118305A1 (en) | 2013-02-01 | 2014-08-07 | Novartis Ag | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
| EP3329935B1 (en) * | 2013-08-24 | 2025-01-08 | Bharat Biotech International Limited | A bacterial vaccine and methods for manufacture thereof |
| EP3110442B1 (en) | 2014-02-28 | 2020-10-14 | GlaxoSmithKline Biologicals SA | Modified meningococcal fhbp polypeptides |
| BE1024634B1 (en) | 2016-04-05 | 2018-05-14 | Gsk Vaccines S.R.L. | IMMUNOGENIC COMPOSITIONS |
| WO2017187448A1 (en) * | 2016-04-25 | 2017-11-02 | National Institute Of Immunology | A novel conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate |
| CN106990188B (en) * | 2017-06-09 | 2019-11-15 | 齐齐哈尔医学院 | A high-performance liquid chromatography detection method for Pseudomonas aeruginosa exotoxin A |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
-
1998
- 1998-12-04 AU AU16261/99A patent/AU1626199A/en not_active Abandoned
- 1998-12-04 WO PCT/US1998/025746 patent/WO2000033882A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000033882A1 (en) | 2000-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1626199A (en) | A vi-repa conjugate vaccine for immunization against salmonella typhi | |
| AU4781297A (en) | Vaccines | |
| EP0682945A3 (en) | Oral sustained release preparation. | |
| AU2120197A (en) | Salmonella typhimurium vaccine | |
| AU4070097A (en) | Mucosal immunogens for novel vaccines | |
| PL362988A1 (en) | Vaccine | |
| HUP9601466A2 (en) | Adjuvants for viral vaccines | |
| AU2001258279A1 (en) | Adjuvant for vaccines | |
| HUP9601462A2 (en) | Adjuvants for viral vaccines | |
| HUP0005010A3 (en) | Salmonella vaccine | |
| AU3154395A (en) | Contraceptive vaccine | |
| AU2769595A (en) | Contraceptive vaccine | |
| AU1144197A (en) | Salmonella vaccines | |
| AU1420897A (en) | Conjugate vaccine for (salmonella paratyphi) a | |
| ZA9711565B (en) | Vaccine | |
| AU3038697A (en) | Meningococcal vaccine | |
| IL143808A0 (en) | Oral vaccine against diarrhea | |
| GB9704977D0 (en) | FIV vaccine | |
| PL346645A1 (en) | IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE | |
| AU5739999A (en) | Salmonella typhi vaccine compositions | |
| IL109519A0 (en) | Vaccines for oral immunization against infecting agents | |
| ZA98738B (en) | Mutant enterotoxin effective as a non-toxic adjuvant for hiv. | |
| AU3360797A (en) | Vaccine against gastro-intestinal nematodes | |
| AUPM370894A0 (en) | Improved adjuvant for vaccines | |
| HK1042041A (en) | Oral vaccine against diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |